Functional Genetics and Development, The Roslin Institute, The University of Edinburgh, Edinburgh, UK.
J Endocrinol. 2020 May;245(2):R11-R22. doi: 10.1530/JOE-19-0460.
The physiological mineralisation of skeletal tissues, as well as the pathological mineralisation of soft tissues involves a fine balance between regulators that either promote or inhibit the process. In recent years, several studies have advocated a non-skeletal role for some of these mineralisation regulators in a range of human diseases, including diabetes, cardiovascular disease, obesity and neurodegenerative disease. This is an emerging area of interest and the functional roles and mechanisms of action of these various endocrine factors, phosphatases and phosphodiesterase's in important pathologies are the focus of this review. Mechanistic insight of the pathways through which these acknowledged regulators of skeletal mineralisation act beyond the skeleton has the potential to identify druggable targets for commonly experienced morbidities, notably those related to metabolism and metabolic syndrome.
骨骼组织的生理矿化以及软组织的病理性矿化涉及到促进或抑制这一过程的调节剂之间的微妙平衡。近年来,有几项研究表明,在包括糖尿病、心血管疾病、肥胖症和神经退行性疾病在内的多种人类疾病中,这些矿化调节剂中的一些具有非骨骼作用。这是一个新兴的研究领域,这些各种内分泌因子、磷酸酶和磷酸二酯酶在重要病理中的功能作用和作用机制是本综述的重点。这些公认的骨骼矿化调节剂在骨骼以外的作用途径的机制研究有可能为常见的病态提供可治疗的靶点,特别是那些与代谢和代谢综合征相关的靶点。